Quick Answer
CNBX Pharmaceuticals Inc. reported Earnings Per Share Diluted of $0.00 per share for the year ending 2025.
- CNBX Pharmaceuticals Inc. showed an increase of +100.0% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from CNBX Pharmaceuticals Inc.'s annual report (Form 10-K), filed with the SEC on December 1, 2025.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: $1.17 (loss) per share | Q4 2021: $0.01 (loss) per share | Q1 2022: $1.01 (loss) per share | Q2 2022: $0.05 (loss) per share | Q4 2022: $0.33 (loss) per share | Q1 2023: $1.33 (loss) per share | Q2 2023: $0.02 (loss) per share | Q4 2023: $0.01 (loss) per share | Q1 2024: $0.01 (loss) per share | Q2 2024: $0.00 per share | Q4 2024: $0.00 (loss) per share | Q1 2025: $0.00 per share | Q2 2025: $0.00 per share | Q4 2025: $0.00 per share.
- Over the full 5 years of available data (2021 to 2025), CNBX Pharmaceuticals Inc.'s Earnings Per Share Diluted has grown by 100.0%.
- Historical annual values: Fiscal year 2025: $0.00 per share | Fiscal year 2024: $0.02 (loss) per share | Fiscal year 2023: $0.42 (loss) per share | Fiscal year 2022: $3.59 (loss) per share | Fiscal year 2021: $0.02 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: